Clinical Trials Browser

OTHER × Ovarian Neoplasms × niraparib × Clear all

NCT04295577 2026-05-13

MONITOR-UK

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04502602 2026-05-11

iNNOVATE

Phase 1 Active not recruiting

Ovarian Neoplasms

NCT06412120 2026-04-23

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Phase 4 Recruiting

Ovarian Neoplasms

NCT06180356 2026-04-22

ANALLISA

Phase 2 Recruiting

Ovarian Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

Phase 2 Recruiting

Ovarian Neoplasms

NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03783949 2025-06-11

EUDARIO

Phase 2 Completed

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Phase 1/2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05990192 2025-04-22

SOPRANO

Phase 2 Recruiting

Ovarian Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

Ovarian Neoplasms, Endometrial Neoplasms

NCT06827353 2025-02-14

OVNI-B

Carcinoma, Ovarian Neoplasms

NCT03891576 2025-01-17

Newton

Phase 2 Terminated

Classical hematologyGynecologic

Anemia, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms, Recurrence, Thrombocytopenia

NCT04507841 2024-12-17

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT03752216 2024-12-13

NiQoLe

Phase 4 Completed

Ovarian Neoplasms

NCT04826198 2024-12-05

REVOCAN

Phase 1/2 Terminated

Ovarian Neoplasms

NCT06614790 2024-10-23

NIRAPARIB

Ovarian Neoplasms

NCT06161493 2024-10-15

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Phase 1 Withdrawn

Ovarian Neoplasms

NCT03598270 2024-08-30

ANITA

Phase 3 Completed

Ovarian Neoplasms

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1 Completed

14 enrolled 12 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04284852 2023-12-15

NEOPRIMA

Phase 2 Completed

Neoplasms, Ovarian Neoplasms

NCT05961124 2023-11-22

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms

NCT03944902 2023-11-21

BRCA

Phase 1 Terminated

Ovarian Neoplasms

NCT05749211 2023-05-16

Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer

Phase NA Unknown

Ovarian Neoplasms

NCT05734911 2023-02-21

Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study

Ovarian Neoplasms

NCT05641506 2022-12-07

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

Phase 2 Unknown

Nausea, Ovarian Neoplasms

NCT02354131 2022-08-30

AVANOVA

Phase 1/2 Completed

Ovarian Neoplasms

NCT05311579 2022-04-13

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Phase 2 Unknown

Ovarian Neoplasms

NCT05187208 2022-01-26

POLO

Phase 4 Unknown

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05044091 2021-09-14

HOPEI

Kenny-Caffey syndrome, Type 1, Ovarian Neoplasms

NCT04217798 2021-09-01

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

Phase 2 Unknown

Ovarian Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

Phase 3 Unknown

Ovarian Neoplasms

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Phase 3 Withdrawn

Ovarian Neoplasms

NCT04785716 2021-03-08

Real-life Use of Niraparib in a Patient Access Program in Norway

Ovarian Neoplasms

NCT04582552 2021-01-20

ROMP

Ovarian Neoplasms

NCT04556071 2020-11-10

AVANIRA3

Phase 2 Unknown

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT03895788 2019-03-29

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

Phase 1 Unknown

Ovarian Neoplasms